Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Ambit Biosciences Inc. today announced the appointment of Michael A. Martino as President, Chief Executive Officer and member of the Board of Directors. Martino brings to Ambit a nearly 30-year track record in leading privately held and publicly traded life sciences companies through late-stage clinical development, fundraising, commercial and business development activities, including new product launches and mergers and acquisitions.  He replaces Alan Lewis, Ph.D., who announced his departure earlier this year and recently left the company after supporting the transition to Martino's appointment.

"We are pleased that Mike, having completed diligence sees what we see: a promising lead drug candidate, quizartinib, with compelling interim data in a high medical need population and valuable earlier-stage assets that together make up an impressive pipeline," said Faheem Hasnain, Ambit's Chairman.  "Mike is joining a talented and committed Ambit team that has successfully moved three drug candidates into the clinic, any one of which could be a lead drug in an earlier stage company, and discovered several promising preclinical compounds. Mike will provide the necessary experience and leadership to drive quizartinib through the approval process and prioritize and focus development of the pipeline."

Martino said, "I am pleased to join Ambit and continue the development of its rich pipeline of early and late-stage programs.  There is tremendous promise in quizartinib where the interim Phase 2 data suggest durable leukemic control in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations who otherwise have very limited treatment options available.  I also look forward to focusing and leading the development of our earlier clinical stage assets, AC430 and AC480, which are targeted at large patient populations with unmet needs."

From 1999 to 2008, Martino served as Presid
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 The ... online demonstration to support life extension technologies and awareness. ... UTC, Universal Coordinated Time, on March 21st 2015, in ... world. , Eric Schulke, Founder of MILE, says, ... act with urgency. The Movement for Indefinite Life Extension ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
(Date:2/26/2015)... Feb. 26, 2015  Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for year ending December 31, 2014 after ... will host a conference call that day at ...
(Date:2/26/2015)... , Feb. 26, 2015   Lexicon Pharmaceuticals, Inc. ... management will present at the Cowen 35 th Annual ... a.m. EST in Boston .  Lexicon management ... milestones. A webcast of the presentation will be ... version of the presentation will be available at www.lexpharma.com ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Pittcon 2015 Announces Exposition Highlights 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... and CYPRESS, Calif., Nov. 15, 2011 Quest Diagnostics ... provider of diagnostic testing, information and services, today announced ... new Simplexa Cytomegalovirus (CMV) molecular test kit on the ... in Europe. The test is designed to enable hospital ...
... strategic effort to refocus and strengthen its organization, the ... planning to make adjustments in the direction, roles, responsibilities ... made by Denise Brown, FRA Interim Executive Director, who ... board of directors with four of the area,s most ...
... LA JOLLA, Calif., Nov. 15, 2011 DermTech, ... disease detection, announced  it will present results from ... can be used with a high-throughput, low-cost qRT-PCR ... recapitulated on a qRT-PCR system that successfully discriminated ...
Cached Biology Technology:Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 2Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 3Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors 2DermTech's Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study 2DermTech's Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study 3
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... cool lily look-alike. This new pinkish-purple ornamental flower, just patented ... but when left in the garden, it blooms all summer ... freeze in the fall., The new hybrid of the Inca ... professor, is a non-fragrant perennial that is set apart by ...
... Biomolecular Sciences (SBS) WHAT: Latest Findings and Research ... April 6-10, 2008 WHERE: SBS 14th ... More than 2,500 researchers and professionals in ... to attend the 14th Annual Conference & Exhibition of the ...
... of UPMCs Chief of the Division of Pediatric Neurosurgery ... the Childrens Brain Tumor Foundation for his pioneering work ... project, Molecular Makers of Outcome in Childhood Oligodendrogliomas, Dr. ... that he says has previously not been well studied ...
Cached Biology News:Cornell patents a pink lily look-alike that blooms all summer long 2Children's Hospital neurosurgeon receives grant 2